Phase 3 Multiple Sclerosis, Relapsing-Remitting Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb194 enrolled33 locationsNCT06408259
Recruiting
Phase 3
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Demyelinating DiseasesMultiple SclerosisNervous System Diseases+3 more
Amsterdam UMC, location VUmc200 enrolled1 locationNCT05834855
Active
Phase 3
Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study One
Multiple Sclerosis, Relapsing-Remitting
Genzyme Corporation581 enrolled15 locationsACTRN12608000435381
Active
Phase 3
Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study Two
Multiple Sclerosis, Relapsing-Remitting
Genzyme Corporation700 enrolled21 locationsACTRN12608000426381